Alteplase

Generic Name
Alteplase
Brand Names
Activase, Cathflo, Cathflo Activase
Drug Type
Biotech
Chemical Formula
-
CAS Number
105857-23-6
Unique Ingredient Identifier
1RXS4UE564
Background

Alteplase is a recombinant tissue plasminogen activator (rt-PA) used as a thrombolytic agent. It cleaves plasminogen to form plasmin, an enzyme involved in the degradation of fibrin clots. In the absence of fibrin, the alteplase-mediated conversion of plasminogen is limited, thanks to the high affinity between alteplase and fibrin. Alteplase is a purified glycoprotein of 527 amino acids expressed in Chinese hamster ovary (CHO) cells. It was first approved by the FDA in 1987 for the management of thromboembolic disease, including acute myocardial infarction (AMI). The use of alteplase to manage AMI has decreased thanks to the availability of safer treatments such as angioplasty and stenting. However, its use for the treatment of acute ischemic stroke (AIS) has increased over the years. New thrombolytic agents derived from tissue plasminogen activator, such as desmoteplase, tenecteplase and reteplase, have also been developed. Alteplase is also available as Cathflo Activase (intracatheter instillation) for the restoration of function to central venous access devices.

Indication

Alteplase is indicated for the treatment of acute ischemic stroke (AIS) and for use in acute myocardial infarction (AMI) for the reduction of mortality and incidence of heart failure. Alteplase is also indicated for the lysis of acute massive pulmonary embolism, defined as acute pulmonary emboli obstructing blood flow to a lobe or multiple lung segments, and acute pulmonary emboli accompanied by unstable hemodynamics.

Associated Conditions
Acute Ischemic Stroke, Cardiac mortality, Heart Failure, Pulmonary Embolism Acute Massive, Central venous access device thrombosis
Associated Therapies
-

Prolonged Hemodialysis Catheter Survival With Copolymer Coating and Rt-PA

First Posted Date
2012-08-22
Last Posted Date
2012-08-22
Lead Sponsor
Centre Hospitalier du Centre du Valais
Target Recruit Count
240
Registration Number
NCT01670474
Locations
🇨🇭

Centre Hospitalier du Centre du Valais (CHCVs), Sion, Valais, Switzerland

Safety of Intravenous Thrombolytics in Stroke on Awakening

Phase 2
Completed
Conditions
Interventions
First Posted Date
2012-07-18
Last Posted Date
2017-04-17
Lead Sponsor
Johns Hopkins University
Target Recruit Count
20
Registration Number
NCT01643902
Locations
🇺🇸

The Johns Hopkins Hospital, Baltimore, Maryland, United States

🇺🇸

Johns Hopkins Bayview Medical Center, Baltimore, Maryland, United States

Intra-arterial Thrombolysis for Severe Recent Central Retinal Vein Occlusion

First Posted Date
2012-04-20
Last Posted Date
2018-08-06
Lead Sponsor
Weill Medical College of Cornell University
Target Recruit Count
1
Registration Number
NCT01581411
Locations
🇺🇸

Weill Cornell Medical College/ New York Presbyterian hospital, New York, New York, United States

Efficacy and Safety of MRI-based Thrombolysis in Wake-up Stroke

Phase 3
Completed
Conditions
Interventions
First Posted Date
2012-02-02
Last Posted Date
2018-10-11
Lead Sponsor
Universitätsklinikum Hamburg-Eppendorf
Target Recruit Count
501
Registration Number
NCT01525290
Locations
🇩🇪

Charite - Universitätsmedizin Berlin, Berlin, Germany

🇩🇪

University Medical Center Hamburg-Eppendorf, Hamburg, Germany

🇬🇧

University of Glasgow, Glasgow, United Kingdom

and more 4 locations

Alteplase-Tenecteplase Trial Evaluation for Stroke Thrombolysis- (ATTEST)

Phase 2
Completed
Conditions
Interventions
First Posted Date
2011-11-17
Last Posted Date
2018-08-03
Lead Sponsor
NHS Greater Glasgow and Clyde
Target Recruit Count
104
Registration Number
NCT01472926
Locations
🇬🇧

Southern General Hospital, Glasgow, Scotland, United Kingdom

Wake up Symptomatic Stroke - Benefit of Intravenous Clot Busters or Endovascular Intervention

First Posted Date
2011-10-20
Last Posted Date
2012-03-30
Lead Sponsor
Jacobs Neurological Institute
Target Recruit Count
90
Registration Number
NCT01455935
Locations
🇺🇸

Millard Fillmore Gates Circle Hospital, Buffalo, New York, United States

Comparison of Different TRansesophageal Echocardiography Guided thrOmbolytic Regimens for prosthetIc vAlve Thrombosis

First Posted Date
2011-10-13
Last Posted Date
2011-10-13
Lead Sponsor
Kartal Kosuyolu Yuksek Ihtisas Education and Research Hospital
Target Recruit Count
182
Registration Number
NCT01451320
Locations
🇹🇷

Kosuyolu Kartal Heart Training and Research Hospital, Istanbul, Turkey

Intraventricular Tissue Plasminogen Activator (tPA) in the Management of Aneurysmal Subarachnoid Hemorrhage

First Posted Date
2010-04-05
Last Posted Date
2010-11-11
Lead Sponsor
University of Calgary
Target Recruit Count
12
Registration Number
NCT01098890
Locations
🇨🇦

Foothills Medical Center, Calgary, Alberta, Canada

New Acute Treatment for Stroke - The Effect of Remote PERconditioning

First Posted Date
2009-09-14
Last Posted Date
2011-06-23
Lead Sponsor
Aarhus University Hospital
Target Recruit Count
120
Registration Number
NCT00975962
Locations
🇩🇰

Department of Neurology, Aarhus University Hospital, Aarhus, Denmark

Study of the Combination Therapy of Rt-PA and Eptifibatide to Treat Acute Ischemic Stroke

First Posted Date
2009-05-07
Last Posted Date
2014-04-17
Lead Sponsor
University of Cincinnati
Target Recruit Count
126
Registration Number
NCT00894803
Locations
🇺🇸

West Virginia University Hospital, Morgantown, West Virginia, United States

🇺🇸

UCLA Ronald Reagan Medical Center, Los Angeles, California, United States

🇺🇸

UCLA Medical Center Santa Monica, Santa Monica, California, United States

and more 17 locations
© Copyright 2024. All Rights Reserved by MedPath